Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SPNS2 | Q8IVW8 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11512287 | 1.00 | HSD11B1 (0.36) | HSD11B1SPNS2TLR7ALDH1A1KCNH2 | |
| SCHEMBL11510230 | 1.00 | HSD11B1 (0.36) | HSD11B1SPNS2TLR7ALDH1A1KCNH2 | |
| SCHEMBL8166391 | 1.00 | HSD11B1 (0.36) | HSD11B1SPNS2TLR7ALDH1A1KCNH2 | |
| SCHEMBL4388847 | 0.92 | ALDH1A1 (0.41) | HSD11B1ALDH1A1HRH3LMNA | |
| SCHEMBL8173050 | 0.81 | TSHR (0.35) | HSD11B1SPNS2TLR7ALDH1A1KCNH2 | |
| SCHEMBL11510482 | 0.79 | KDM4E (0.37) | HSD11B1SPNS2ALDH1A1KCNH2CETP | |
| SCHEMBL11805405 | 0.79 | ALDH1A1 (0.49) | SPNS2TLR7ALDH1A1KCNH2CETP | |
| SCHEMBL8062006 | 0.79 | ALDH1A1 (0.49) | SPNS2TLR7ALDH1A1KCNH2CETP | |
| SCHEMBL9677868 | 0.79 | ALDH1A1 (0.49) | SPNS2TLR7ALDH1A1KCNH2CETP | |
| SCHEMBL9222262 | 0.79 | ALDH1A1 (0.49) | SPNS2TLR7ALDH1A1KCNH2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829588-B2 | Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-09 | — | — | US | disclosed |
| US-7829588-B2 | Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-09 | — | — | US | disclosed |
| US-7829588-B2 | Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-09 | — | — | US | disclosed |
| EP-1694669-B1 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2007-04-11 | — | — | EP | disclosed |
| EP-1694669-B1 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-03-08 | — | — | US | disclosed |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-03-08 | — | — | US | disclosed |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1694669-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058844-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | PPARG, PPARA, PPARD | HSD11B1 415/4885SPNS2 4266/4885TLR7 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.